gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Taxol inhibits significantly an experimentally induced peritoneal carcinomatosis depending on the application mode

Meeting Abstract

  • corresponding author presenting/speaker Arndt Hribaschek - Klinik für Chirurgie, Universitätsklinikum, Magdeburg, Deutschland
  • Frank Meyer - Klinik für Chirurgie, Universitätsklinikum, Magdeburg
  • Matthias Pross - Klinik für Chirurgie, Universitätsklinikum, Magdeburg
  • Karsten Ridwelski - Klinik für Chirurgie, Städtisches Klinikum, Magdeburg
  • Dörthe Küster - Institut für Pathologie, Universitätsklinikum, Magdeburg
  • Hans Lippert - Klinik für Chirurgie, Universitätsklinikum, Magdeburg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO460

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Hribaschek et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Peritoneal carcinomatosis in colorectal carcinoma is still an unsolved problem in the oncological treatment since there are no established treatment protocols available.

The aim of the study was to investigate whether i) the chemotherapeutic drug Taxol & ii) the various modes of drug application generate an impact on intraperitoneal (i.p.) tumor growth, which was experimentally induced by a transfer of tumor cells (5x1.000.000) of a colon carcinoma cell line (CC-531) into the abdominal cavity of WAG rats (weight, 250-260g). The rats were divided into 3 groups (gr.; n=6 per gr.). Taxol (170 mg/qm) was given either via the i.p. or intravenous (i.v.) route using a port-a-cath. Chemotherapy - gr.1: None; gr.2: On day (d)5,10&15; gr.3: On d15,20&25 to mimic early (gr.2) & late (gr.3) chemotherapy in the postoperative course (port-a-cath for gr. 2 & 3). On the 30th d, rats were sacrificed; tumor weight of the greater omentum & mesenteric tissue, No. of metastases, volume of ascites, & tumor-specific characteristics were determined.

Results: Tumor weight [g] (Greater omentum/Mesenteric site) - gr.1: 4.58+0.55/5.26+0.62; gr.2: 0.94+0.68*/2.57+0.18* (i.p.) versus 3.05+0.47/3.76+0.25 (i.v.); gr.3: 3.92+0.22/4.68+0.24 (i.p.) versus 4.01+0.17/4.98+0.37 (i.v.) [*, P > 0.05; t test; SPSS for Windows]. Using early i.p. administration of Taxol, a significant reduction of tumor-associated parameters such as number of nodal tumor lesions at the peritoneum, hepatic & pulmonary metastases as well as volume of ascites was achieved.

Taken together, Taxol generated a significantly inhibitory effect on the i.p. tumor growth. Direct i.p. administration of Taxol induced a distinct inhibition of peritoneal carcinomatosis compared with the i.v. mode. I.p. administration of Taxol is more effective using the early postoperative regimen.

In conclusion, Taxol appears to be a potential chemotherapeutic drug providing a significant effect in the therapeutic management of peritoneal carcinomatosis under experimental conditions.